昭衍新藥(603127.SH):部分行使超額配股權、穩定價格行動及穩定價格期結束
格隆匯 3 月 21日丨昭衍新藥(603127.SH)公吿,根據公司於2020年9月15日召開的2020年第四次臨時股東大會會議通過的決議,公司股東大會就本次發行上市授予簿記管理人不超過本次發行H股股數15%的超額配股權。根據資本市場情況,公司本次發行上市聯席全球協調人(代表國際包銷商)已於2021年3月19日部分行使超額配股權,涉及合共40,800股H股(以下簡稱“超額配發股份”),相當於任何超額配股權獲行使前全球發售項下初步可供認購的發售股份總數約0.09%。
公司將按每股H股151.00港元(不包括1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費)(即全球發售下每股H股發售價)發行及配發超額配發股份。上市委員會已批准超額配發股份上市及買賣。預期超額配發股份將於2021年3月24日上午九時正於聯交所主板開始上市及買賣。
公司進一步宣佈,全球發售的穩定價格期已於2021年3月21日(星期日)(即遞交香港公開發售申請的截止日期起計第30日)結束。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.